Brand name: Mozobil TM
Active ingredients: plerixafor
What it is used for
MOZOBIL is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilise haematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma and multiple myeloma (MM).
How to take it
The way to take this medicine is: Subcutaneous. This medicine is injected, usually with a short needle or pen-like device, into the fat just beneath the skin.
- Store below 25 degrees Celsius
- Shelf lifetime is 3 Years.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
Clear, colourless to pale yellow solution
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Is this medicine subsidised?
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on April 1, 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Pregnant or planning a pregnancy?
For the active ingredient plerixafor
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Consumer Medicines Information (CMI)
For side effects, taking other medicines and more
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems